Sargent Investment Group LLC Buys Shares of 13,265 DexCom, Inc. (NASDAQ:DXCM)

Sargent Investment Group LLC bought a new position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 13,265 shares of the medical device company's stock, valued at approximately $906,000.

Several other institutional investors have also bought and sold shares of DXCM. Teachers Retirement System of The State of Kentucky grew its stake in DexCom by 16.7% in the first quarter. Teachers Retirement System of The State of Kentucky now owns 136,968 shares of the medical device company's stock valued at $9,353,000 after acquiring an additional 19,607 shares during the period. Kestra Private Wealth Services LLC grew its position in shares of DexCom by 18.5% in the first quarter. Kestra Private Wealth Services LLC now owns 13,086 shares of the medical device company's stock valued at $894,000 after purchasing an additional 2,039 shares during the last quarter. Financial Harvest LLC acquired a new stake in DexCom during the first quarter worth approximately $756,000. C WorldWide Group Holding A S boosted its holdings in shares of DexCom by 28.7% in the 1st quarter. C WorldWide Group Holding A S now owns 449,000 shares of the medical device company's stock valued at $30,662,000 after purchasing an additional 100,000 shares in the last quarter. Finally, Jennison Associates LLC raised its holdings in shares of DexCom by 37.7% during the 1st quarter. Jennison Associates LLC now owns 10,523,246 shares of the medical device company's stock worth $718,632,000 after buying an additional 2,879,489 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company's stock.

Insider Buying and Selling

In other DexCom news, EVP Michael Jon Brown sold 10,000 shares of DexCom stock in a transaction on Friday, May 23rd. The shares were sold at an average price of $84.28, for a total transaction of $842,800.00. Following the sale, the executive vice president owned 95,602 shares in the company, valued at $8,057,336.56. The trade was a 9.47% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Sadie Stern sold 6,184 shares of the business's stock in a transaction on Tuesday, May 27th. The stock was sold at an average price of $85.11, for a total value of $526,320.24. Following the sale, the executive vice president owned 109,621 shares of the company's stock, valued at approximately $9,329,843.31. The trade was a 5.34% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 27,190 shares of company stock worth $2,281,732. 0.32% of the stock is currently owned by company insiders.

DexCom Stock Down 0.2%

DXCM stock opened at $83.89 on Friday. The company has a quick ratio of 1.32, a current ratio of 1.50 and a debt-to-equity ratio of 0.55. DexCom, Inc. has a fifty-two week low of $57.52 and a fifty-two week high of $113.28. The firm's 50-day simple moving average is $84.49 and its 200 day simple moving average is $80.19. The stock has a market cap of $32.89 billion, a PE ratio of 62.60, a price-to-earnings-growth ratio of 1.79 and a beta of 1.44.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical device company reported $0.32 earnings per share for the quarter, missing the consensus estimate of $0.33 by ($0.01). DexCom had a net margin of 12.90% and a return on equity of 30.05%. The business had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1.02 billion. During the same quarter last year, the business posted $0.32 EPS. The business's revenue for the quarter was up 12.5% on a year-over-year basis. As a group, sell-side analysts predict that DexCom, Inc. will post 2.03 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on DXCM shares. Robert W. Baird dropped their target price on DexCom from $115.00 to $105.00 and set an "outperform" rating on the stock in a report on Friday, May 2nd. Wall Street Zen upgraded DexCom from a "hold" rating to a "buy" rating in a report on Friday. Mizuho boosted their target price on DexCom from $95.00 to $100.00 and gave the company an "outperform" rating in a research note on Wednesday. Morgan Stanley upped their price target on DexCom from $82.00 to $89.00 and gave the company an "equal weight" rating in a research report on Tuesday, July 15th. Finally, Canaccord Genuity Group increased their target price on DexCom from $103.00 to $106.00 and gave the stock a "buy" rating in a research report on Friday, May 2nd. Four investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $99.60.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.